Faron Pharmaceuticals Oy Product Pipeline Review 2012 New Report


Naperville, IL -- (SBWIRE) -- 12/17/2012 -- Faron Pharmaceuticals Oy - Product Pipeline Review - 2012 provides data on the Faron Pharmaceuticals Oy’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.


- Faron Pharmaceuticals Oy - Brief Faron Pharmaceuticals Oy overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Faron Pharmaceuticals Oy human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Faron Pharmaceuticals Oy with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Faron Pharmaceuticals Oy’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Faron Pharmaceuticals Oy’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Faron Pharmaceuticals Oy in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Faron Pharmaceuticals Oy’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Faron Pharmaceuticals Oy.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Faron Pharmaceuticals Oy and identify potential opportunities in those areas.

To view table of contents for this market report please visit: